Abstract |
The main disadvantages of glucagon-like peptide 1 (GLP-1) are its rapid degradation and excretion. These bottlenecks can be overcome by lipidation or other structural modification. The aim of this study was to design a series of long-acting GLP-1 analogues based on our previously discovered Xenopus GLP-1 analogs (1-3). The structure-activity relationship around lipidated 1-3 derivatives (1a-3l) with respect to in vitro potency as well as protraction was firstly explored. Compound 3g was selected for further modification. The Gly2 of 3g was replaced with Aib2, and a lactam constraint between Glu16 and Lys20 (i to i + 4) was introduced to further improve the in vivo activity and stability, affording compound 4. The receptor activation capability and in vitro stability of 4 were better than 3g and liraglutide. In addition, the hypoglycemic and insulinotropic activity of 4 was significantly better than liraglutide in db/db mice. Moreover, the enhanced in vitro stability of 4 translated into improved in vivo pharmacokinetic profiles and a prolonged antidiabetic duration. Administration of 4 twice daily for one week in diet-induced obese mice caused a significant decrease in food intake, body fat and body weight. The five-week treatment study on db/db mice of 4 further demonstrated the therapeutic effects of 4 on body weight, HbA1c and glucose tolerance. These preclinical studies demonstrate the therapeutic potential of 4 for type 2 diabetes and obesity. The present study also suggests that combined lipidation and conformational constraint strategy has potential to be used for improving the therapeutic properties of peptides.
|
Authors | Jing Han, Yue Huang, Xinyu Chen, Feng Zhou, Yingying Fei, Junjie Fu |
Journal | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
(Eur J Pharm Sci)
Vol. 123
Pg. 111-123
(Oct 15 2018)
ISSN: 1879-0720 [Electronic] Netherlands |
PMID | 30031858
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 Elsevier B.V. All rights reserved. |
Chemical References |
- Delayed-Action Preparations
- Hypoglycemic Agents
- Lipids
- Xenopus Proteins
- Glucagon-Like Peptide 1
|
Topics |
- Animals
- Delayed-Action Preparations
(chemistry)
- Diabetes Mellitus, Type 2
(drug therapy)
- Glucagon-Like Peptide 1
(analogs & derivatives, pharmacology)
- HEK293 Cells
- Humans
- Hypoglycemic Agents
(chemistry, pharmacology)
- Lipids
- Male
- Mice, Inbred C57BL
- Molecular Conformation
- Rats, Sprague-Dawley
- Structure-Activity Relationship
- Xenopus Proteins
(chemistry, pharmacology)
|